FDA Approves Lucentis for Treatment of Retinal Vein Occlusion

June 25, 2010

After a six-month review, the FDA has updated the indication for the injectable macular degeneration drug ranibizumab (Lucentis) for the treatment of retinal vein occlusion. The approval was based on the results of two studies that pooled data from 789 patients with macular edema after central and branch retinal vein occlusion, comparing results using 0.3 mg and 0.5 mg ranibizumab injections against placebo with best-corrected visual acuity ratings after six months.

Read the full story here on MedPage Today.




Jump down to form below to submit your own comments

4 Responses to “FDA Approves Lucentis for Treatment of Retinal Vein Occlusion”

  • Elise Leval

    Ari and JD thank both of you for your kind responses to my query. I wil be very grateful if you will let me know of any new developments in this area. I just don’t want to believe that I am condemned to blindness in one eye for the rest of my life. I keep trying to imagine the cluster of skill sets, working together, that would be required to find a solution. Bio, nano, optic, and imagination. I’m convinced that some innovative group will take up the challenge.

    Again, thanks very much, and good luck in your individual endeavors.

    Elise Leval

  • JD Bliss

    You may want to reach out to the folks who undertook this clinical trial on Transcorneal Electrical Stimulation Therapy for Retinal Disease:


  • ari

    not treatable/reversible, unless caught in the first few hours- then, injecting clot-busting drug (like used in heart attacks) may help. once the retina and/or optic nerve dies from lack of blood, it’s hopeless, and there is no research in this area, except stem cells to regenerate tissue– which is decades away.

  • Elise Leval

    Is central retinal artery occlusion (CRAO) treatable or is it irreversible? Is any research being done in this area? Are clinical trials in progress? What is the long term prognosis?